The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Before Science Day
https://avacta.com/avacta-to-host-therapeutics-division-science-day-on-23rd-february-2023/
I feel the emphasis has changed a little. RP2D used to carry equal emphasis to MTD, which I understood would be useful if MTD could not be determined. And with precision making the toxin safer I understand why RP2D maybe preferrable.
We are supposed to hear of price sensitive information in an RNS rather than second hand via the Science Day.
The last RNS mentioned Dox in tumours has been observed at therapeutic levels. I read this as shrinking the tumour.
It also reads like they need to decide on which tumours to include. So narrower. Which ones are left out must be a difficult decision.
https://beta.clinicaltrials.gov/study/NCT04969835?distance=50&term=Ava6000&rank=1&fbclid=IwAR2zhqu08YeStyGFkir3Vp76YQkyNdLOkfMTGJEX2i8LnLhrtM2HaxxpMqs&fs=e&s=cl